Drugs / autologous tumor cell vaccine
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01339663 | Mar → Dec 2012 | metastatic melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00469820 | Apr 2007 → Mar 2010 | leukemia, plasma cell neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00098917 | Feb 2005 → ? | lung cancer | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00100971 | Apr 2004 → Mar 2007 | leukemia | Boston Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00085488 | Feb 2004 → Feb 2006 | cutaneous melanoma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00020462 | Feb 2001 → ? | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00023985 | Jan 2001 → Jul 2003 | lung cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00126685 | Apr 2005 → ? | cutaneous melanoma | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen | Unknown | No outcome recorded |
| Phase 1/2 | NCT00016133 | Mar 2001 → Aug 2004 | colorectal cancer | Intracel | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT00436930 | Dec 2006 → Oct 2012 | cutaneous melanoma | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00343447 | Aug 2006 → May 2007 | leukemia | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Withdrawn | No outcome recorded |
| Phase 2 | NCT00093522 | Aug 2004 → ? | kidney cancer | St. Luke's Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT00085436 | Dec 2003 → Oct 2009 | kidney cancer | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00003386 | Jul 1999 → Apr 2001 | ovarian carcinoma | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Phase 2 | NCT00003715 | Dec 1998 → ? | cutaneous melanoma | AVAX Technologies | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00014573 | Aug 1998 → Oct 2004 | brain cancer | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00003185 | Aug 1997 → Jul 1998 | central nervous system neoplasm | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00004024 | Jun 1997 → Jan 2004 | central nervous system neoplasm | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00004022 | Jun 1997 → Jan 2004 | cutaneous melanoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00019097 | Jul 1995 → Mar 2007 | plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002475 | Apr 1991 → Dec 2007 | breast cancer, colorectal cancer, kidney cancer, lung cancer +2 | St. Vincent Medical Center - Los Angeles | Completed | No outcome recorded |
| Phase 2 | NCT00002454 | Dec 1971 → ? | precancerous condition | University of Medicine and Dentistry of New Jersey | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous tumor cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00126685 ↗ |
| Known as | TCV | “autologous tumor cell vaccines (TCV)” PMID 32316978 ↗ Apr 2020 |
| Action | Deplete | “Vaccines made from a patient's tumor tissue may make the body build an immune response to kill tumor cells.” NCT00002475 ↗ |
| Modality | Vaccine | “Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.” NCT00002454 ↗ |
| Route | Other | “Dinitrophenyl (DNP)-modified autologous ovarian epithelial cell vaccine and BCG adjuvant are injected once a week beginning on day 3 and continuing for 6 weeks.” NCT00003386 ↗ |